TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:32
Akoya Biosciences Inc. ( AKYA ) https://www.akoyabio.com
2.46USD
Sector:
Healthcare
Industry:
Medical Instruments & Supplies
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-51.57%
AKYA
SPY
32.66%
-81.98%
AKYA
SPY
108.59%
AKYA
0.00%
SPY
302.52%
AKYA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
119.30
162.99
0.07
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.06
1.37
8.75
-34.93
0.00
-3.90
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-44.38
62.32
-52.74
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-33.21
-34.77
0.00
Other Earnings and Cash Flow Stats:
Akoya Biosciences Inc. ( AKYA ) Net Income TTM ($MM) is -57.97
Akoya Biosciences Inc. ( AKYA ) Operating Income TTM ($MM) is -49.84
Akoya Biosciences Inc. ( AKYA ) Owners' Earnings Annual ($MM) is 0.00
Akoya Biosciences Inc. ( AKYA ) Current Price to Owners' Earnings ratio is 0.00
Akoya Biosciences Inc. ( AKYA ) EBITDA TTM ($MM) is -41.93
Akoya Biosciences Inc. ( AKYA ) EBITDA Margin is -52.74%
Capital Allocation:
Akoya Biosciences Inc. ( AKYA ) has paid 0.00 dividends per share and bought back -0.52784 million shares in the past 12 months
Akoya Biosciences Inc. ( AKYA ) has increased its debt by 0.91700000000002 million USD in the last 12 months
Capital Structure:
Akoya Biosciences Inc. ( AKYA ) Interest-bearing Debt ($MM) as of last quarter is 79
Akoya Biosciences Inc. ( AKYA ) Annual Working Capital Investments ($MM) are 7
Akoya Biosciences Inc. ( AKYA ) Book Value ($MM) as of last quarter is 13
Akoya Biosciences Inc. ( AKYA ) Debt/Capital as of last quarter is 583%
Other Balance Sheet Stats:
Akoya Biosciences Inc. ( AKYA ) has 12 million in cash on hand as of last quarter
Akoya Biosciences Inc. ( AKYA ) has 27 million of liabilities due within 12 months, and long term debt 75 as of last quarter
Akoya Biosciences Inc. ( AKYA ) has 49 common shares outstanding as of last quarter
Akoya Biosciences Inc. ( AKYA ) has 0 million USD of preferred stock value
Academic Scores:
Akoya Biosciences Inc. ( AKYA ) Altman Z-Score is -2.56 as of last quarter
Akoya Biosciences Inc. ( AKYA ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Akoya Biosciences Inc. ( AKYA ) largest shareholder is Renaissance Technologies Corp owning 212600 shares at 0.52 ($MM) value
McKelligon Brian(an insider) Sold 7500 shares of Akoya Biosciences Inc. ( AKYA ) for the amount of $15630.00 on 2024-06-11
11.09% of Akoya Biosciences Inc. ( AKYA ) is held by insiders, and 70.19% is held by institutions
Akoya Biosciences Inc. ( AKYA ) went public on 2021-04-16
Other Akoya Biosciences Inc. ( AKYA ) financial metrics:
FCF:-48.68
Unlevered Free Cash Flow:0.00
EPS:-0.85
Operating Margin:-44.38
Gross Profit Margin:62.32
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-309.04
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Akoya Biosciences Inc. ( AKYA ) :
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.